Physician profile
Stephen P Anthony
NPI 1053307298
$737.53
in general payments reported to CMS, 2019-2025
20 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.33 · 2022: $165 · 2023: $41.40 · 2024: $261 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $119.83 | 2020-2023 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $102.56 | 2024-2025 | Imfinzi, Enhertu, Onglyza |
| Emd Serono, INC. | $57.64 | 2022-2025 | |
| Amgen INC. | $55.78 | 2022-2025 | Tezspire |
| Harmony Biosciences LLC | $49.19 | 2023-2024 | Wakix |
| Janssen Biotech, INC. | $41.62 | 2024-2025 | Erleada, Tecvayli, Darzalex |
| Tersera Therapeutics LLC | $30.25 | 2024 | Zoladex |
| Novartis Pharmaceuticals Corporation | $28.53 | 2024 | |
| Pfizer INC. | $28.18 | 2025 | |
| Beigene USA, INC. | $26.66 | 2025 | Brukinsa |
| Genzyme Corporation | $25.35 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.52 | 2024 | |
| Servier Pharmaceuticals LLC | $24.35 | 2024 | |
| Macrogenics, INC. | $21.87 | 2022 | |
| Sobi, INC | $21.48 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $21.05 | 2025 | Orgovyx |
| Syndax Pharmaceuticals, INC. | $20.95 | 2025 | |
| Astellas Pharma US INC | $20.68 | 2025 | Vyloy |
| Lilly USA, LLC | $17.04 | 2024 | Verzenio, Jaypirca |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.